Photodynamic Therapy for Malignant Mesothelioma
Author Information
Author(s): H.-B. Ris, H.J. Altermatt, R. Inderbitzi, R. Hess, B. Nachbur, J.C.M. Stewart, Q. Wang, C.K. Lim, R. Bonnett, M.C. Berenbaum, U. Althaus
Primary Institution: University of Bern, Switzerland
Hypothesis
Can photodynamic therapy with mTHPC improve treatment outcomes for patients with diffuse malignant mesothelioma?
Conclusion
Intraoperative photodynamic therapy using mTHPC showed promising tumoricidal effects in patients with diffuse malignant mesothelioma.
Supporting Evidence
- mTHPC concentration was up to 14 times higher in the tumor than in normal tissues.
- A light dose of 10 Joules cm-2 caused a 10 mm deep tumor necrosis after administration of 0.3 mg kg-1 mTHPC.
- The only side effect observed was mild skin photosensitivity.
Takeaway
Doctors used a special light and a medicine called mTHPC to help treat four patients with a serious lung disease, and it seemed to work well in killing the bad cells.
Methodology
Four patients received mTHPC-PDT after surgery, with varying doses of mTHPC and light delivered to tumor areas.
Potential Biases
Potential bias due to the small sample size and lack of randomization.
Limitations
The study involved a small number of patients and lacked a control group for comparison.
Participant Demographics
Four male patients aged 46 to 65, all with possible asbestos exposure.
Want to read the original?
Access the complete publication on the publisher's website